FDA Class I recall: alarm and electrical faults in the controller (AIC) for the Impella heart pump — distributed worldwide (Abiomed)

The U.S. FDA classified Abiomed's device recall as Class I — its most serious class (use may cause serious adverse health consequences or death) — recall number Z-2238-2026, reported June 3, 2026, status ongoing.

The affected product is the Automated Impella Controller (AIC). Impella is a small circulatory-support pump (a catheter-based heart pump placed within the heart) that temporarily supports blood circulation in patients whose heart pumping function is reduced; the AIC is the console that drives and monitors that pump.

The reasons (a retrospective submission) include: (1) alarm failures, power-path faults, electrical-short risks, and inaccurate motor-current sensing identified in certain AIC consoles; and (2) improper alignment between the purge cassette and the motor drive, which can cause a piston-block event so that purge-system priming cannot be completed, requiring the user to switch to a backup AIC console. The quantity is 625 units; distribution spans the U.S. nationwide plus Canada, Denmark, France, Germany, Italy, Kuwait, the Netherlands, and others.

Why it matters: Impella supports circulation in critically ill cardiac patients and during high-risk heart procedures — a device tied directly to life support. Alarm failures or electrical/drive faults in its controller could mean it does not work correctly when support is needed, or that a switch to a backup unit is required — with serious implications for patient safety. That gravity is why the FDA classified it Class I. Distribution spans several markets in the Americas and Europe — a useful pointer for hospital clinical-engineering and patient-safety teams to check affected models and actions. Follow official FDA information and the manufacturer's notice (this article is general organization, not medical advice).